Welcome to our dedicated page for Regenxbio SEC filings (Ticker: RGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regenxbio鈥檚 gene-therapy disclosures can span hundreds of pages filled with trial protocols, FDA correspondence, and complex licensing terms. Finding the cash runway buried in a 10-K or spotting an ABBV-RGX-314 milestone in an 8-K shouldn鈥檛 take your entire day.
Our platform solves that problem. Stock Titan鈥檚 AI reads every Regenxbio quarterly earnings report 10-Q filing, Regenxbio annual report 10-K simplified, and Regenxbio 8-K material events explained the moment they hit EDGAR. It then delivers plain-English summaries, red-flags key risk factors, and links the numbers to trial timelines鈥攑erfect for understanding Regenxbio SEC documents with AI rather than parsing biotech jargon yourself.
Need to monitor insider sentiment? AG真人官方-time alerts surface Regenxbio Form 4 insider transactions, letting you gauge executive confidence before the market reacts. Curious about compensation? The latest Regenxbio proxy statement executive compensation is broken down line by line. Whether you鈥檙e tracking Regenxbio insider trading Form 4 transactions, reviewing manufacturing disclosures, or running a quick Regenxbio earnings report filing analysis, every filing type鈥�10-K, 10-Q, 8-K, S-3, DEF 14A鈥攊s indexed, searchable, and annotated. Skip the PDFs; get the insights that matter.
REGENXBIO Inc. (RGNX) 鈥� Form 4 Insider Transaction
Chief Executive Officer and Director Curran Simpson reported a Code F transaction on 07/01/2025 involving 4,701 shares of RGNX common stock. Code F indicates shares were withheld by the company to satisfy tax obligations upon the vesting of previously granted restricted stock units (RSUs) dated 07/01/2024. The shares were valued at $8.23, the closing price on the vesting date.
Following the withholding, Simpson鈥檚 direct beneficial ownership stands at 252,331 common shares. No open-market purchase or sale occurred, and no derivative securities were exercised or disposed of.
- Transaction type: tax-related share withholding (non-cash).
- Remaining ownership suggests continued alignment with shareholders.
- No new options, warrants, or other derivatives reported.
The filing is routine and carries limited market impact, primarily confirming the executive鈥檚 updated share count.
The SEC has declared REGENXBIO's Form S-3 registration statement effective as of June 25, 2025 at 4:00 P.M. The registration statement was filed under file number 333-288053.
Form S-3 is a simplified security registration form used by companies that have already met certain reporting requirements. This effectiveness notice indicates that REGENXBIO can now proceed with their planned securities offering as outlined in the registration statement.
This is a significant development for REGENXBIO (NASDAQ: RGNX) as it provides them with the ability to:
- Access the public markets for capital raising
- Issue various types of securities as described in their registration statement
- Execute their financing strategy through shelf offerings
REGENXBIO has filed a prospectus for the potential resale of up to 268,096 shares of common stock by a selling stockholder. These shares are issuable through a warrant with an exercise price of $14.92 per share, connected to a May 2025 Loan Agreement with HealthCare Royalty Management.
Key financial points:
- Potential proceeds of $4.0 million if warrant is fully exercised
- Current stock price: $8.56 (as of June 24, 2025)
- Trading symbol: RGNX on Nasdaq Global Select Market
REGENXBIO is a clinical-stage biotechnology company focused on gene therapy using their proprietary NAV庐 Technology Platform. Their platform utilizes AAV vectors for gene delivery, including AAV8 and AAV9. The company has multiple ongoing clinical trials including AAVIATE庐, AFFINITY BEYOND庐, ALTITUDE庐, and ATMOSPHERE庐. Key partnerships include collaborations with AbbVie for ABBV-RGX-314 and Nippon Shinyaku for RGX-121 and RGX-111 development.
FAQ
What is the current stock price of Regenxbio (RGNX)?
What is the market cap of Regenxbio (RGNX)?
What is Regenxbio's core technology?
Which diseases are targeted by Regenxbio's therapies?
How does the NAV庐 platform differentiate Regenxbio's products?
What is significant about one-time treatments in gene therapy?
Who are Regenxbio's strategic collaborators?
How does Regenxbio generate revenue?
What are the key clinical programs of Regenxbio?
How does Regenxbio ensure high-quality manufacturing?
